CD38 and lung carcinoma: These data from our laboratory provide strong rationale for the use of CD38 inhibition in conjunction with immune checkpoint inhibitors in order to combat acquired resistance, and indeed have found that combinations of blocking antibodies towards CD38 and PD-(L)1 provide a robust response in preclinical models of lung cancer.